AT
Akash Tewari Jefferies Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Ionis Pharmaceuticals
IONS
$9.46B
| $59.35 | $96 |
62%
upside
| Buy | 2 days ago |
|
2
Regeneron Pharmaceuticals
REGN
$60.1B
| $567.22 | $831 |
47%
upside
| Buy | 8 days ago |
|
3
Arvinas
ARVN
$559M
| $7.61 | $10 |
31%
upside
| Hold | 4 months ago |
|
4
Bristol-Myers Squibb
BMY
$95B
| $46.69 | $68 |
46%
upside
| Buy | 4 months ago |
|
5
BioMarin Pharmaceuticals
BMRN
$10.9B
| $56.75 | $95 |
67%
upside
| Outperform | 9 months ago |
|
6
BioNTech
BNTX
$24.9B
| $103.50 | $150 |
45%
upside
| Buy | 11 months ago |
|
7
Relay Therapeutics
RLAY
$690M
| $4 | $16 |
300%
upside
| Buy | 11 months ago |
|
8
Neurocrine Biosciences
NBIX
$13.9B
| $140.40 | $189 |
35%
upside
| Buy | 1 year ago |
|
9
Apellis Pharmaceuticals
APLS
$3.62B
| $28.65 | $80 |
179%
upside
| Buy | 1 year ago |
|
10
Eli Lilly
LLY
$666B
| $742.91 | $1,015 |
37%
upside
| Buy | 1 year ago |
|
11
Alkermes
ALKS
$4.77B
| $28.92 | $50 |
73%
upside
| Buy | 1 year ago |
|
12
Apogee Therapeutics
APGE
$2.21B
| $37.13 | $75 |
102%
upside
| Buy | 1 year ago |
|
|
13
Apogee Therapeutics
APGE
$2.21B
| $37.13 | $95 |
156%
upside
| Buy | 1 year ago |
|
14
Spyre Therapeutics
SYRE
$1.03B
| $16.99 | $31 |
82%
upside
| Buy | 1 year ago |
|
15
Pfizer
PFE
$140B
| $24.54 | $39 |
59%
upside
| Buy | 1 year ago |
|
16
argenx
ARGX
$44.9B
| $733.66 | $513 |
30%
downside
| Buy | 2 years ago |
|
17
Terns Pharmaceuticals
TERN
$618M
| $7.06 | $18 |
155%
upside
| Buy | 2 years ago |
|
18
Merck
MRK
$210B
| $84.05 | $125 |
49%
upside
| Buy | 2 years ago |
|
19
Zymeworks
ZYME
$1.07B
| $14.08 | $11 |
22%
downside
| Buy | 2 years ago |
|
|
20
BioMarin Pharmaceuticals
BMRN
$10.9B
| $56.75 | $120 |
111%
upside
| Buy | 2 years ago |
|
21
Cytokinetics
CYTK
$5.95B
| $49.75 | $75 |
51%
upside
| Buy | 3 years ago |
|
22
Madrigal Pharmaceuticals
MDGL
$9.61B
| $431.21 | $151 |
65%
downside
| Buy | 3 years ago |
|
23
Exelixis
EXEL
$10.1B
| $37.38 | $28 |
25%
downside
| Buy | 3 years ago |
|
|
24
Cytokinetics
CYTK
$5.95B
| $49.75 | $50 |
1%
upside
| Outperform | 4 years ago |
|
|
25
Exelixis
EXEL
$10.1B
| $37.38 | $35 |
6%
downside
| Outperform | 4 years ago |
|